Our Firm receives frequent inquiries from Lipitor patients who are concerned that the statin resulted in their Type 2 diabetes diagnosis. We are pleased that the federal Lipitor litigation is moving forward.
New York, New York (PRWEB) May 21, 2014
Hundreds of Lipitor lawsuits (http://www.lipitorlawsuitcenter.com/) that allege use of the cholesterol-lowering statin resulted in the development of Type 2 diabetes continue to move forward in the U.S. District Court, District of South Carolina, Bernstein Liebhard LLP reports. According to a Case Management Order issued on May 16, 2014, the parties have each been directed to choose seven Lipitor lawsuits for a Discovery Pool, from which the Court will ultimately select a case for the proceeding’s first bellwether trial. The Plaintiffs’ Steering Committee is to notify the Court of its seven selections by June 20, 2014. Attorneys for the Defendants will make their selections known by June 24, 2014. On December 15, 2014, the Court will randomly select one of those 14 cases for the proceeding’s first trial, which will begin on or after July 1, 2015. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)
“Our Firm receives frequent inquiries from Lipitor patients who are concerned that the statin resulted in their Type 2 diabetes diagnosis. We are pleased that the federal Lipitor litigation is moving forward,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Lipitor lawsuit reviews to individuals who took the statin and later developed Type 2 diabetes.
Lipitor Diabetes Allegations
According to court documents, all of the Lipitor lawsuits pending in the District of South Carolina similarly allege that use of the statin increases a patient’s risk of developing Type 2 diabetes. Plaintiffs further claim that Pfizer, Inc. was aware of the link between Lipitor and diabetes before modifying the drug’s label in February 2012 to reflect this risk, but concealed this information in order to protect the drug’s market share. The complaints also maintain that diabetes information added to the Lipitor label in 2012 remains inadequate.
Court records indicate that the litigation involving Lipitor and diabetes has been growing since January 2012, following publication of a study in JAMA: Internal Medicine the previous month which suggested that post-menopausal women treated with statins faced an increased risk of developing new-onset Type 2 diabetes.* A month later, U.S. Food & Drug Administration (FDA) ordered the manufacturers of statins like Lipitor to update their labels with information about the drugs’ potential association with the disease.
Alleged victims of Lipitor and diabetes may be entitled to compensation from Pfizer, Inc. for their injury-related damages. To learn more about Lipitor diabetes allegations, please visit Bernstein Liebhard LLP’s website, or call 800-511-5092 to obtain a free legal review.
*archinte.jamanetwork.com/article.aspx?articleid=1108676, JAMA Internal Medicine, January 2012
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993? As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com